Can Sanofi’s venglustat priority review change the treatment outlook for type 3 Gaucher disease?
Sanofi’s venglustat could target neurological type 3 Gaucher disease. The FDA review now tests whether rare disease care can shift.
Sanofi’s venglustat could target neurological type 3 Gaucher disease. The FDA review now tests whether rare disease care can shift.